NYSE:CHE

Chemed Stock Forecast, Price & News

$473.08
+1.41 (+0.30 %)
(As of 09/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$469.78
$475.61
50-Day Range
$451.98
$485.08
52-Week Range
$417.41
$560.00
Volume77,040 shs
Average Volume93,085 shs
Market Capitalization$7.44 billion
P/E Ratio25.41
Dividend Yield0.31%
Beta0.45
30 days | 90 days | 365 days | Advanced Chart
Receive CHE News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemed and its competitors with MarketBeat's FREE daily newsletter.


Chemed logo

About Chemed

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

3.07 out of 5 stars

Medical Sector

7th out of 1,352 stocks

Home Health Care Services Industry

1st out of 10 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 3.3Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Chemed (NYSE:CHE) Frequently Asked Questions

Is Chemed a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed
or view top-rated stocks.

What stocks does MarketBeat like better than Chemed?

Wall Street analysts have given Chemed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chemed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Chemed?

Chemed saw a increase in short interest in August. As of August 13th, there was short interest totaling 198,000 shares, an increase of 12.5% from the July 29th total of 176,000 shares. Based on an average trading volume of 90,500 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.3% of the shares of the stock are sold short.
View Chemed's Short Interest
.

When is Chemed's next earnings date?

Chemed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Chemed
.

How were Chemed's earnings last quarter?

Chemed Co. (NYSE:CHE) released its quarterly earnings data on Monday, July, 26th. The company reported $4.60 earnings per share for the quarter, topping the Zacks' consensus estimate of $4.29 by $0.31. The firm had revenue of $532.26 million for the quarter, compared to analyst estimates of $511.85 million. Chemed had a net margin of 14.30% and a trailing twelve-month return on equity of 35.40%. Chemed's quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.41 earnings per share.
View Chemed's earnings history
.

How has Chemed's stock price been impacted by COVID-19 (Coronavirus)?

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CHE shares have increased by 14.3% and is now trading at $473.08.
View which stocks have been most impacted by COVID-19
.

How often does Chemed pay dividends? What is the dividend yield for Chemed?

Chemed declared a quarterly dividend on Friday, August 6th. Stockholders of record on Monday, August 16th will be given a dividend of $0.36 per share on Thursday, September 2nd. This represents a $1.44 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, August 13th. This is a boost from Chemed's previous quarterly dividend of $0.34.
View Chemed's dividend history
.

Is Chemed a good dividend stock?

Chemed pays an annual dividend of $1.44 per share and currently has a dividend yield of 0.31%. Chemed has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 7.96%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.45% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

What guidance has Chemed issued on next quarter's earnings?

Chemed issued an update on its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided EPS guidance of $18.200-$18.500 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.350. The company issued revenue guidance of -.

What price target have analysts set for CHE?

2 brokerages have issued 12-month price targets for Chemed's shares. Their forecasts range from $580.00 to $609.00. On average, they anticipate Chemed's share price to reach $594.50 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts' price targets for Chemed
or view top-rated stocks among Wall Street analysts.

Who are Chemed's key executives?

Chemed's management team includes the following people:
  • Kevin J. McNamara, President, Chief Executive Officer & Director (LinkedIn Profile)
  • David Patrick Williams, Chief Financial Officer & Executive Vice President
  • Spencer S. Lee, Executive Vice President
  • Nicholas M. Westfall, Executive Vice President
  • Thomas C. Hutton, Director & Vice President

What is Kevin J. McNamara's approval rating as Chemed's CEO?

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Chemed's key competitors?

What other stocks do shareholders of Chemed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

What is Chemed's stock symbol?

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Who are Chemed's major shareholders?

Chemed's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.57%), BlackRock Inc. (9.01%), Neuberger Berman Group LLC (3.77%), Kayne Anderson Rudnick Investment Management LLC (2.78%), State Street Corp (2.71%) and Wells Fargo & Company MN (2.53%). Company insiders that own Chemed stock include Andrea R Lindell, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends for Chemed
.

Which major investors are selling Chemed stock?

CHE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, Invesco Ltd., FMR LLC, Renaissance Technologies LLC, Virginia Retirement Systems ET AL, Teacher Retirement System of Texas, and Deutsche Bank AG. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Nicholas Michael Westfall, Spencer S Lee, and Thomas P Rice.
View insider buying and selling activity for Chemed
or view top insider-selling stocks.

Which major investors are buying Chemed stock?

CHE stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Ninety One UK Ltd, Kayne Anderson Rudnick Investment Management LLC, Bank of America Corp DE, Bank of America Corp DE, State Street Corp, Woodline Partners LP, and Point72 Asset Management L.P..
View insider buying and selling activity for Chemed
or or view top insider-buying stocks.

How do I buy shares of Chemed?

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemed's stock price today?

One share of CHE stock can currently be purchased for approximately $473.08.

How much money does Chemed make?

Chemed has a market capitalization of $7.44 billion and generates $2.08 billion in revenue each year. The company earns $319.47 million in net income (profit) each year or $18.08 on an earnings per share basis.

How many employees does Chemed have?

Chemed employs 15,544 workers across the globe.

When was Chemed founded?

Chemed was founded in 1970.

What is Chemed's official website?

The official website for Chemed is www.chemed.com.

Where are Chemed's headquarters?

How can I contact Chemed?

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at (513) 762-6690.


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.